Which is a more important risk factor for L-DOPA-induced dyskinesia, age at onset of Parkinson's disease or age at L-DOPA treatment for Parkinson's disease?

被引：0
|
作者：
Kimura, Tamaki [1 ]
Tomiyama, Masahiko [1 ]
Arai, Akira [1 ]
Suzuki, Chieko [1 ]
Shouji, Mikio [1 ]
机构：
[1] Hirosaki Univ, Hirosaki, Aomori, Japan
来源：
NEUROSCIENCE RESEARCH | 2008年 / 61卷
关键词：
D O I：
暂无
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
引用
收藏
页码：S203 / S203
页数：1
相关论文
共 50 条
  • [21] Possible role for chlorpheniramine in the treatment of l-DOPA induced dyskinesia in Parkinson’s disease
    Petros N. Karamanakos
    Periklis Pappas
    Marios Marselos
    Pharmacy World & Science, 2008, 30 : 1 - 2
  • [22] Possible role for chlorpheniramine in the treatment of L-DOPA induced dyskinesia in Parkinson's disease
    Karamanakos, Petros N.
    Pappas, Periklis
    Marselos, Marios
    PHARMACY WORLD & SCIENCE, 2008, 30 (01): : 1 - 2
  • [23] Polymorphisms of Dopamine Receptor Genes and Risk of L-Dopa-Induced Dyskinesia in Parkinson's Disease
    Comi, Cristoforo
    Ferrari, Marco
    Marino, Franca
    Magistrelli, Luca
    Cantello, Roberto
    Riboldazzi, Giulio
    Bianchi, Maria Laura Ester
    Bono, Giorgio
    Cosentino, Marco
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (02)
  • [24] Nalbuphine Efficacy for L-Dopa-induced Dyskinesia in Parkinson Disease
    Mouradian, M. Maral
    Papa, Stella M.
    Voronkov, Michael
    Braithwaite, Steven P.
    NEUROTHERAPEUTICS, 2016, 13 (03) : 650 - 650
  • [25] First candidates of susceptibility to l-dopa induced dyskinesia in parkinson's disease
    Charbonnier-Beaupel, F.
    Malerbi, M.
    Alcacer, C.
    Tahiri, K.
    Cormier, F.
    Carpentier, W.
    Herve, D.
    Girault, J. A.
    Corvol, J. C.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2012, 26 : 15 - 15
  • [26] Peculiarities of L-DOPA treatment of Parkinson’s disease
    R. M. Kostrzewa
    P. Nowak
    J. P. Kostrzewa
    R. A. Kostrzewa
    R. Brus
    Amino Acids, 2005, 28 : 157 - 164
  • [27] Targeting β-arrestin2 in the treatment of L-DOPA-induced dyskinesia in Parkinson's disease
    Urs, Nikhil M.
    Bido, Simone
    Peterson, Sean M.
    Daigle, Tanya L.
    Bass, Caroline E.
    Gainetdinov, Raul R.
    Bezard, Erwan
    Caron, Marc G.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2015, 112 (19) : E2517 - E2526
  • [28] Peculiarities of L-DOPA treatment of Parkinson's disease
    Kostrzewa, RM
    Nowak, P
    Kostrzewa, JP
    Kostrzewa, RA
    Brus, R
    AMINO ACIDS, 2005, 28 (02) : 157 - 164
  • [29] The effects of zonisamide on L-DOPA-induced dyskinesia in Parkinson's disease model mice
    Sano, Hiromi
    Nambu, Atsushi
    NEUROCHEMISTRY INTERNATIONAL, 2019, 124 : 171 - 180
  • [30] Inhibition of mTOR Signaling in Parkinson's Disease Prevents L-DOPA-Induced Dyskinesia
    Santini, Emanuela
    Heiman, Myriam
    Greengard, Paul
    Valjent, Emmanuel
    Fisone, Gilberto
    SCIENCE SIGNALING, 2009, 2 (80) : ra36
12345